Product Description
please call me , to know more
AI Product Description
*The following content is generated by AI and is for reference only.
Octreotide Acetate is a synthetic analog of the naturally occurring hormone somatostatin, widely recognized in clinical medicine for its potent inhibitory effects on various endocrine and neuroendocrine secretions. With the chemical formula C49H66N10O10S2 and the CAS registry number 8315-72-2, this compound acts as a long-acting formulation that mimics the biological activity of native somatostatin but with significantly enhanced stability and duration of action. Structurally, it consists of an octapeptide sequence modified to resist rapid enzymatic degradation by peptidases, allowing for sustained therapeutic efficacy through subcutaneous or intramuscular administration.
The primary clinical applications of Octreotide Acetate revolve around the management of acromegaly, a condition characterized by excessive growth hormone secretion often caused by pituitary adenomas. By suppressing growth hormone release, it helps normalize insulin-like growth factor 1 levels and alleviates associated symptoms such as joint pain, headaches, and soft tissue swelling. Furthermore, it serves as a critical intervention for patients suffering from carcinoid syndrome, effectively controlling severe diarrhea and flushing episodes associated with neuroendocrine tumors of the gastrointestinal tract. It is also utilized in treating VIPomas, rare pancreatic tumors that cause profuse watery diarrhea, and in managing bleeding esophageal varices due to portal hypertension. Additionally, the drug plays a role in reducing postoperative complications following pancreatic surgery. Its mechanism involves binding to specific somatostatin receptors (subtypes 2 and 5) on target cells, thereby inhibiting the release of multiple hormones including glucagon, gastrin, and insulin. As a cornerstone therapy in endocrinology and oncology, Octreotide Acetate offers a vital tool for improving quality of life and survival rates in patients with complex hormonal disorders.